Status:
COMPLETED
Vigor and the LDR in Parkinson Disease
Lead Sponsor:
University of Michigan
Collaborating Sponsors:
National Institute of Neurological Disorders and Stroke (NINDS)
Conditions:
Parkinson Disease
Eligibility:
All Genders
45-90 years
Phase:
PHASE4
Brief Summary
Parkinson disease (PD) is a common disorder in which reduced speed of movement results from inadequate brain production of the chemical dopamine. The most effective treatment for PD is the drug levo-d...
Detailed Description
Dopamine replacement therapy (DRT) is the standard symptomatic treatment for early to moderate Parkinson disease (PD). In early to moderate PD, the most important DRT component is the Long Duration Re...
Eligibility Criteria
Inclusion
- Diagnosis of Parkinson Disease
- Previously Untreated or treated for \<4 weeks
- Mild to Moderate Parkinson disease (Hoehn \& Yahr Stages I-II)
- About to start treatment with a L-Dopa preparation (Sinemet)
Exclusion
- The presence of other neurologic disease or findings on examination
- Depression: Geriatric Depression Scale score \>11
- Use of dopamine agonists or stimulants
- Evidence of a stroke or mass lesion on prior structural brain imaging (MRI or CT)
- Evidence of any confounding medical or psychiatric problem that would preclude task participation.
- Participants with cognitive impairment that might impair their capacity to provide informed consent.
Key Trial Info
Start Date :
February 12 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 25 2024
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT04821830
Start Date
February 12 2020
End Date
April 25 2024
Last Update
July 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan
Ann Arbor, Michigan, United States, 48109